Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.
Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, Caraglia M, Ferrarini M, Giordano A, Tagliaferri P, Tassone P. Rossi M, et al. Among authors: conforti f. J Cell Physiol. 2013 Jul;228(7):1506-15. doi: 10.1002/jcp.24306. J Cell Physiol. 2013. PMID: 23254643
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.
Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, Foresta U, Piro E, Ferrara F, Amorosi A, Bahlis N, Anderson KC, Munshi N, Tagliaferri P, Causa F, Tassone P. Calimeri T, et al. Among authors: conforti f. Leukemia. 2011 Apr;25(4):707-11. doi: 10.1038/leu.2010.300. Epub 2011 Jan 14. Leukemia. 2011. PMID: 21233838 Free PMC article. No abstract available.
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: conforti f. Clin Cancer Res. 2012 Nov 15;18(22):6260-70. doi: 10.1158/1078-0432.CCR-12-1708. Epub 2012 Oct 3. Clin Cancer Res. 2012. PMID: 23035210 Free PMC article.
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gullà AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, Caraglia M, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Amodio N, et al. Among authors: conforti f. Cell Death Dis. 2012 Nov 29;3(11):e436. doi: 10.1038/cddis.2012.175. Cell Death Dis. 2012. PMID: 23190608 Free PMC article.
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: conforti f. Oncotarget. 2013 Feb;4(2):242-55. doi: 10.18632/oncotarget.820. Oncotarget. 2013. PMID: 23479461 Free PMC article.
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma.
Rossi M, Altomare E, Botta C, Gallo Cantafio ME, Sarvide S, Caracciolo D, Riillo C, Gaspari M, Taverna D, Conforti F, Critelli P, Bertucci B, Iannone M, Polerà N, Scumaci D, Arbitrio M, Amodio N, Di Martino MT, Paiva B, Tagliaferri P, Tassone P. Rossi M, et al. Among authors: conforti f. Leukemia. 2021 Mar;35(3):823-834. doi: 10.1038/s41375-020-0947-1. Epub 2020 Jul 6. Leukemia. 2021. PMID: 32632096
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D, Riillo C, Ballerini A, Gaipa G, Lhermitte L, Rossi M, Botta C, Duroyon E, Grillone K, Gallo Cantafio ME, Buracchi C, Alampi G, Gulino A, Belmonte B, Conforti F, Golino G, Juli G, Altomare E, Polerà N, Scionti F, Arbitrio M, Iannone M, Martino M, Correale P, Talarico G, Ghelli Luserna di Rorà A, Ferrari A, Concolino D, Sestito S, Pensabene L, Giordano A, Hildinger M, Di Martino MT, Martinelli G, Tripodo C, Asnafi V, Biondi A, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: conforti f. J Immunother Cancer. 2021 Feb;9(2):e002026. doi: 10.1136/jitc-2020-002026. J Immunother Cancer. 2021. PMID: 33597219 Free PMC article.
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas.
Polerà N, Mancuso A, Riillo C, Caracciolo D, Signorelli S, Grillone K, Ascrizzi S, Hokanson CA, Conforti F, Staropoli N, Gervasi L, Di Martino MT, Arbitrio M, Nisticò G, Crea R, Tagliaferri P, Juli G, Tassone P. Polerà N, et al. Among authors: conforti f. Cancers (Basel). 2023 Mar 8;15(6):1647. doi: 10.3390/cancers15061647. Cancers (Basel). 2023. PMID: 36980534 Free PMC article.
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D, Polerà N, Belmonte B, Conforti F, Signorelli S, Gulino A, Staropoli N, Tuccillo FM, Bonelli P, Juli G, Grillone K, Ascrizzi S, Cirillo M, Migale L, Ballerini A, Pelizon C, Di Martino MT, Tagliaferri P, Riillo C, Tassone P. Caracciolo D, et al. Among authors: conforti f. Br J Haematol. 2024 Feb;204(2):555-560. doi: 10.1111/bjh.19183. Epub 2023 Nov 14. Br J Haematol. 2024. PMID: 37963444
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma.
Grillone K, Ascrizzi S, Cremaschi P, Amato J, Polerà N, Croci O, Rocca R, Riillo C, Conforti F, Graziano R, Brancaccio D, Caracciolo D, Alcaro S, Pagano B, Randazzo A, Tagliaferri P, Iorio F, Tassone P. Grillone K, et al. Among authors: conforti f. Blood. 2024 Oct 17;144(16):1705-1721. doi: 10.1182/blood.2023021991. Blood. 2024. PMID: 39158066 Free PMC article.
416 results